8 results about "C-terminus" patented technology

The present inventors succeeded in improving the antibody constant region to have increased stability under acid conditions, reduced heterogeneity originated from disulfide bonds in the hinge region, reduced heterogeneity originated from the H chain C terminus, and increased stability at high concentrations as well as in discovering novel constant region sequences having reduced Fcγ receptor-binding, while minimizing the generation of novel T-cell epitope peptides. As a result, the present inventors successfully discovered antibody constant regions with improved physicochemical properties (stability and homogeneity), immunogenicity, safety, and pharmacokinetics.

The application discloses a kind of MS2 virus-like particles based on capsid protein site-directed mutation and its preparation method and application, belong to molecular biological technique field.The amino acid of the beta sheet interface of capsid protein sequence, the amino acid of the interface when two capsid proteins molecules assemble, the carboxyl end site of capsid protein is subjected to site-directed mutation, obtain the mutant that can significantly improve the assembly efficiency and stability of capsid protein dimer.Utilize the mutant to construct MS2 virus-like particles, further by the design of mature enzyme and capsid protein expression element, control mature enzyme weak expression, capsid protein strong expression, to improve assembly efficiency.The application improves the assembly efficiency of MS2 virus by the above strategy, improves the proportion of wrapped RNA, enhances the stability of virus-like particle, greatly prolongs the stable storage time of RNA, improves the purity of wrapped RNA.

This invention relates to the field of biomedical technology, specifically to a stabilized and modified herpes zoster virus gE protein, its preparation method, and its applications. The stabilized and modified herpes zoster virus gE protein of this invention is obtained through cysteine ​​mutation modification and structural design optimization, and exhibits improved expression levels, thermal stability, and immunogenicity compared to recombinant varicella-zoster virus gE protein with only the removal of the carboxyl-terminal hydrophobic transmembrane region and intracellular tail.

The present invention revealed that translating an mRNA that encodes a peptide containing an unnatural amino acid in a translation system that contains a ribosome containing an engineered L31 protein can increase the amount of the translated peptide. Furthermore, the invention revealed that by using this ribosome, the relative amount of by-products can also be reduced. An engineered L31 protein of the present invention has an amino acid sequence with deletion of 6 or more amino acid residues from the C terminus in the amino acid sequence of the wild-type Escherichia coli L31 protein.

The present application relates to the technical field of biological medicine, in particular to a kind of stable modified varicella-zoster virus gE protein, its preparation method and application.The stable modified varicella-zoster virus gE protein of the present application is obtained by cysteine mutation modification and structure design optimization, compared with the recombinant varicella-zoster virus gE protein with only carboxy-terminal hydrophobic transmembrane region and intracellular tail removed, has improved expression, thermal stability and immunogenicity.

This application relates to the field of microbial engineering technology, specifically to a *Yersinia lipolytica* yeast, its application, and a method for producing conjugated linolenic acid (CLNA). This application provides a *Yersinia lipolytica* yeast, with accession number CGMCCNO.39103, and provides its application in producing CLNA. It also provides a method for producing CLNA, comprising the following steps: (1) inoculating a *Yersinia lipolytica* yeast strain into a culture medium rich in linolenic acid substrate, fermenting to obtain a *Yersinia lipolytica* yeast strain rich in CLNA; (2) extracting fatty acids using an organic solvent to obtain CLNA. The *Yersinia lipolytica* yeast strain of this application not only produces high levels of CLNA, but also synthesizes CLNA with conjugated double bonds located at carbon atoms 11, 13, and 15 at the carboxyl terminus, similar to natural CLNA; furthermore, the method for producing CLNA has the advantages of high efficiency and low cost.

This invention discloses a novel thermostable RNase HI sequence mutant, its preparation method, and its applications. First, it discloses the thermostable RNase HI sequence mutant with the amino acid sequence shown in SEQ ID NO.1. It further discloses the preparation method and applications of the aforementioned thermostable RNase HI sequence mutant. This invention's thermostable RNase HI sequence mutant incorporates a novel sequence fused to the carboxyl terminus of wild-type thermostable RNase HI. It can be overexpressed in prokaryotic hosts and purified in large quantities via affinity chromatography and ion exchange chromatography, significantly increasing yield. Under the same conditions, it exhibits significantly improved enzyme activity and thermostable properties compared to the wild type, which is of great significance for optimizing enzyme performance and greatly reduces the production cost of commercially available thermostable RNase HI. This will promote the widespread application of thermostable RNase HI in various fields.